

In the Claims:

1. (currently amended) An orally administrable film-shaped medicament comprising at least one rapidly disintegrating or freely soluble active substance-containing layer and at least one slowly or non-disintegrating active substance-containing layer, said at least one active substance being selected from the group consisting of deoxypeganine, pharmaceutically acceptable salts of deoxypeganine, [[and a]] deoxypeganine derivative derivatives and pharmaceutically acceptable salts of deoxypeganine derivatives.
2. (cancelled)
3. (previously presented) The medicament according to claim 1, wherein said medicament is suitable for transmucosal administration of said at least one active substance.
4. (previously presented) The medicament according to claim 1, wherein said medicament has at least one polymer-containing layer which serves as an active substance reservoir and contains said at least one active substance, and wherein said polymer portion is present in an amount between 10 to 90%-wt.
5. (previously presented) The medicament according to claim 1, wherein said medicament has a multilayer structure, wherein at least one layer contains an active substance selected from the group consisting of deoxypeganine, deoxypeganine derivatives and salts of deoxypeganine and deoxypeganine derivatives.
6. (previously presented) The medicament according to claim 1, wherein the content of said at least one active substance is 0.5 to 40%-wt.
7. (previously presented) The medicament according to claim 1, wherein the overall

thickness of said medicament is 0.05 to 3 mm.

8. (previously presented) The medicament according to claim 1, wherein said medicament is mucoadhesive.

9. (previously presented) The medicament according to claim 1, wherein said medicament is soluble in an aqueous media, and wherein the dissolution takes place between 1 second and 5 minutes.

10. (previously presented) The medicament according to claim 1, wherein said medicament is quickly disintegratable in an aqueous media, and wherein the disintegration takes place within 1 second to 5 minutes.

11. (previously presented) The medicament according to claim 1, wherein said medicament is gelatinizable or swellable in an aqueous media.

12. (previously presented) The medicament according to claim 1, wherein said medicament releases said at least one active substance over a period of time of up to 8 hours.

13. (previously presented) The medicament according to claim 1, wherein said medicament has at least one rapidly releasing active substance-containing layer and at least one layer with retarded active substance release.

14. (previously presented) The medicament according to claim 1, wherein said medicament additionally contains at least one further pharmaceutically active substance which is selected from the group consisting of acetylcholinesterase inhibitors and opiate antagonists.

15. (previously presented) The film-shaped medicament according to claim 1, wherein

said medicament contains at least one auxiliary substance.

16. (withdrawn) A use of at least one cholinergic active substance acting on the central nervous system selected from the at least one active substance recited in claim 1 for producing an oral, film-shaped medicament for administering said at least one active substance for treating diseases or symptoms caused by acetylcholine deficiency or where such a deficiency occurs, as well as for treating at least one of diseases where a deficiency of endogenous amine occurs and diseases which can be favourably influenced by inhibition of monoaminooxidase, said use comprising the step of introducing said medicament into the oral cavity at intervals between 1 and 6 hours and wherein the daily dose of said at least one active substance is between 50 and 750 mg.

17. (withdrawn) The use according to claim 16, wherein said film-shaped medicament is a medicament according to claim 1.

18. (withdrawn) The use according to claim 16, wherein the medicament is used for treating Alzheimer's disease or symptoms caused by Alzheimer's disease.

19. (withdrawn) The use according to claim 16, wherein the medicament is used for treating a condition selected from the group of conditions consisting of depressions, schizophrenia and manic disorders.

20. (withdrawn) The use according to claim 16, wherein the medicament is used for treating chronic fatigue syndrome or disturbed sleep.

21. (withdrawn) The use according to claim 16, wherein the medicament is used for treating abuse of alcohol or for treating abuse of nicotine.

22. (withdrawn) The use according to claim 16, wherein the medicament is used for the therapy of abuse of chemical substances, psychotropic substances, or the dependence on such substances.

23. (withdrawn) The use according to claim 16, wherein the medicament is used for the prophylactic treatment of poisonings caused by organophosphorous cholinesterase inhibitors.

24. (withdrawn) The use according to claim 16, wherein the medicament is used for treating disorders of the central nervous system, which have been caused by the action of psychotropic substances.

25. (previously presented) The medicament according to claim 2, wherein said pharmaceutically acceptable salt of a derivative of deoxypeganine is selected from the group consisting of deoxypeganine hydrochloride and deoxypeganine hydrobromide.

26. (previously presented) The medicament according to claim 3, wherein said medicament is suitable for buccal administration of said at least one active substance.

27. (previously presented) The medicament according to claim 4, wherein said polymer portion is present in an amount between 20 to 70%-wt.

28. (previously presented) The medicament according to claim 27, wherein said polymer portion is present in an amount between 20 to 60%-wt.

29. (previously presented) The medicament according to claim 6, wherein the content of said at least one active substance is 5 to 30%-wt.

30. (previously presented) The medicament according to claim 7, wherein the overall thickness of said medicament is 0.1 to 1 mm.

31. (previously presented) The medicament according to claim 30, wherein the overall thickness of said medicament is 0.1 to 0.5 mm.

32. (previously presented) The medicament according to claim 9, wherein said aqueous media is saliva.

33. (previously presented) The medicament according to claim 9, wherein said dissolution takes place between 3 and 30 seconds.

34. (previously presented) The medicament according to claim 10, wherein said aqueous media is saliva.

35. (previously presented) The medicament according to claim 10, wherein said disintegration takes place within 3 to 30 seconds.

36. (previously presented) The medicament according to claim 11, wherein said aqueous media is saliva.

37. (currently amended) The medicament according to claim 12, wherein said ~~delay in time is medicament releases the at least one active substance over a period of up to 24 hours.~~

38. (withdrawn) The use according to claim 24, wherein the medicament is used for treating disorders of impaired memory.

39. (previously presented) The medicament according to claim 1, wherein said medicament has a two- or three-layer structure, wherein at least one layer contains an active substance selected from the group consisting of deoxypeganine,

deoxypeganine derivatives and salts of deoxypeganine and deoxypeganine derivatives.

40. (previously presented) The medicament according to claim 1, wherein said medicament has at least one mucoadhesive outer surface.